ArticleProstate cancer and prostatic diseases2007
Global analysis of differentially expressed genes in androgen-independent prostate cancer.
Article in Prostate cancer and prostatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Systemic lupus erythematosus and prostate cancer risk: a pool of cohort studies and Mendelian randomization analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- Real world experience with [EJNMMI reports · 2024Article
- Validation of the interaction between PRDX4 and TXNDC5 in gastric cancer and the significance of theTranslational cancer research · 2024Article
- Androgens, aging, and prostate health.Reviews in endocrine & metabolic disorders · 2022Review
- Powerful p-value combination methods to detect incomplete association.Scientific reports · 2021Article
- Folic Acid-Modified miR-491-5p-Loaded ZIF-8 Nanoparticles Inhibit Castration-Resistant Prostate Cancer by Regulating the Expression of EPHX1.Frontiers in bioengineering and biotechnology · 2021Article
- High expression ofOncology letters · 2020Article
- Gene expression feature selection for prostate cancer diagnosis using a two-phase heuristic-deterministic search strategy.IET systems biology · 2018Article
- The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.BMC cancer · 2017Article
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.Oncotarget · 2016Article
- Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.Oncotarget · 2015Article
- Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.EJNMMI research · 2015Article
- The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.Oncogene · 2015Article
- An immunohistochemical study of thioredoxin domain-containing 5 expression in gastric adenocarcinoma.Oncology letters · 2015Article
- Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.Cancer research · 2012Article
- The influence of TXNDC5 gene on gastric cancer cell.Journal of cancer research and clinical oncology · 2010Article
- LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.BMC medical genomics · 2010Article
- Identifying gene-disease associations using centrality on a literature mined gene-interaction network.Bioinformatics (Oxford, England) · 2008Article
- Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.World journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progression to androgen independent (AI) is the main cause of death in prostate cancer, and the mechanism is still unclear. By reviewing the expression profiles of 26 prostate cancer samples in a holistic view, we found a group of genes differentially expressed in AI compared with androgen-dependent groups (P-value<0.01, t-test). Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as thioredoxin domain containing 5 , tumor necrosis factor receptor superfamily, member 10a , ribosomal protein S19 and Janus kinase 2 upregulated in AI prostate cancer, could play important roles in the transition from AD to AI and could be biomarkers of prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.